← Browse by Condition
Medical Condition

hidradenitis suppurativa

Total Trials
4
Recruiting Now
4
Trial Phases
EARLY_Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for hidradenitis suppurativa sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hidradenitis suppurativa Clinical Trials

How many clinical trials are currently recruiting for hidradenitis suppurativa?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for hidradenitis suppurativa, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hidradenitis suppurativa?
hidradenitis suppurativa research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hidradenitis suppurativa clinical trial?
Eligibility criteria for hidradenitis suppurativa trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
2
Top Sponsors
University of Alabama at Birmingham 1 trial
Almirall, S.A. 1 trial
Assistance Publique - Hôpitaux de Paris 1 trial
Shanghai Huaota Biopharmaceutical Co., Ltd. 1 trial

Recruiting Clinical Trials

NCT06326476 EARLY_Phase 1
Recruiting
Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
Enrollment
12 pts
Location
United States
Sponsor
University of Alabama at Birmi...
View Trial →
NCT07547813 Phase 2
Recruiting
A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa
Enrollment
50 pts
Location
Poland
Sponsor
Almirall, S.A.
View Trial →
NCT05531747
Recruiting
Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa
Enrollment
200 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →
NCT06895499 Phase 1, Phase 2
Recruiting
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
Enrollment
15 pts
Location
China
Sponsor
Shanghai Huaota Biopharmaceuti...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology